Andrew Obenshain

2022

In 2022, Andrew Obenshain earned a total compensation of $1.8M as Chief Executive Officer at bluebird bio, a 80% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$386,280
Option Awards$421,830
Salary$643,390
Stock Awards$351,000
Other$12,200
Total$1,814,700

Obenshain received $643.4K in salary, accounting for 35% of the total pay in 2022.

Obenshain also received $386.3K in non-equity incentive plan, $421.8K in option awards, $351K in stock awards and $12.2K in other compensation.

Rankings

In 2022, Andrew Obenshain's compensation ranked 1,918th out of 5,756 executives tracked by ExecPay. In other words, Obenshain earned more than 66.7% of executives.

ClassificationRankingPercentile
All
1,918
out of 5,756
67th
Division
Manufacturing
1,020
out of 3,133
67th
Major group
Chemicals And Allied Products
430
out of 1,419
70th
Industry group
Drugs
395
out of 1,320
70th
Industry
Biological Products, Except Diagnostic Substances
98
out of 291
66th
Source: SEC filing on April 28, 2023.

Obenshain's colleagues

We found three more compensation records of executives who worked with Andrew Obenshain at bluebird bio in 2022.

2022

Jason Cole

bluebird bio

Chief Strategy & Financial Officer former

2022

Richard Colvin

bluebird bio

Chief Medical Officer

2022

Thomas Klima

bluebird bio

Chief Commercial and Operating Officer

News

You may also like